Nasdaq Cdak News Today

Codiak BioSciences (NASDAQ:CDAK – Get Rating) and Century Therapeutics (NASDAQ:IPSC – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 71.3% of Codiak BioSciences shares […]

Codiak BioSciences, Inc. (NASDAQ:CDAK – Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 173,800 shares, a growth of 25.6% from the February 28th total of 138,400 shares. Based on an average trading volume of 176,800 shares, the days-to-cover ratio is […]

Codiak BioSciences, Inc. (NASDAQ:CDAK – Get Rating) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 173,800 shares, a growth of 25.6% from the February 28th total of 138,400 shares. Based on an average daily volume of 176,800 shares, the […]

– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak...

Codiak BioSciences (NASDAQ:CDAK – Get Rating) released its quarterly earnings results on Thursday. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.14, Fidelity Earnings reports. Codiak BioSciences had a negative net margin of 425.30% and a negative return on equity of 169.73%. Shares of CDAK traded up $0.13 […]

– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE,...

CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on...